Who Should Be Tested for Hepatitis C and What Happens When the Result Is Positive

Nobody expects a liver conversation at a check-up booked for a sore knee. Yet that is how many people meet hepatitis C: a clinician glances at the chart, notices there is no record of a hepatitis C test, and adds one to the routine blood draw. The question of who should be tested for hepatitis C used to depend on a list of risk factors that people were often reluctant to admit to. That list has largely given way to something simpler.

The virus is quiet. Most people who carry it feel fine for years, sometimes decades, while it works slowly on the liver. That silence is the reason screening guidelines changed, and it is also the reason a positive result tends to arrive as a shock rather than a confirmation of something already suspected.

This article walks through both halves of that experience: the logic behind who gets tested, and, for the person holding a positive result, what the next appointments, tests and weeks usually look like.

How a hepatitis C test actually works: antibody first, then RNA

A virus is too small to see and too scarce to grow routinely, so laboratories look for its footprints instead. For hepatitis C there are two kinds. The first is the antibody, a protein the immune system makes in response to the virus and keeps producing long after the encounter. The second is the virus’s own genetic material, called RNA, which is present only while the virus is actively copying itself in the body.

Screening starts with the antibody test because it is simple to run and answers a broad question: has this person ever been infected? A positive antibody result cannot tell whether the infection is current or long gone, so a second step is needed. The RNA test, usually done by a method called PCR (polymerase chain reaction, which copies tiny amounts of genetic material until there is enough to detect), settles that. If RNA is found, the virus is present now.

Timing matters. According to the CDC, HCV RNA can usually be detected within 1–2 weeks of exposure, while antibodies typically appear 8–11 weeks after exposure, and in some people later still. That gap is called the window period, and it is why a negative antibody test soon after a needle-stick or shared syringe does not close the question.

Many laboratories now run the two steps automatically, a process called reflex testing: if the antibody comes back positive, the same tube of blood goes straight on to RNA testing. In my view this is the single most important detail to ask about when you have blood drawn, because a meaningful share of people who test antibody-positive never complete the second step, and an unconfirmed antibody result helps nobody.

Who should be tested for hepatitis C at least once?

For years, screening depended on remembering and disclosing risk factors, and it missed a great many people. The CDC’s current recommendation, published in its Morbidity and Mortality Weekly Report, replaced that approach with a universal one: every adult aged 18 or older should be tested for hepatitis C at least once in their lifetime, and every pregnant person should be tested during each pregnancy. The only exception is a setting where the local prevalence of current infection is already known to be very low, a threshold most communities do not meet.

The reasoning is arithmetic. The World Health Organization estimates that around 50 million people worldwide live with chronic hepatitis C infection, most of them unaware of it, because the infection produces few or no symptoms for a long time. A test that waits for symptoms waits too long.

Beyond the universal once-in-adulthood test, CDC guidance singles out groups who should be tested regardless of age:

• anyone who has ever injected drugs, even once and even long ago, or who shared equipment for injecting or snorting;
• people living with HIV;
• people who received a blood transfusion, organ transplant or clotting-factor concentrate before donated blood was routinely screened for the virus;
• people who have ever been on long-term hemodialysis (a machine that filters the blood when the kidneys cannot);
• children born to a mother with hepatitis C;
• anyone with persistently abnormal liver blood tests or a known liver disease;
• health workers or first responders after a needle-stick or other blood exposure.

One more group belongs on any honest list: anyone who simply wants the test. The CDC explicitly supports testing people who ask for it, without requiring them to explain why. The question of who should be tested for hepatitis C has, for practical purposes, become: who has not been tested yet?

Who should be tested for hepatitis C more than once, and who is usually asked to wait

A single negative test is reassuring only for exposures that happened long enough ago for antibodies to form. Two situations call for more than one test.

The first is ongoing risk. The CDC recommends periodic testing for people who currently inject drugs and share equipment, and for people on maintenance hemodialysis. How often is not fixed in stone; clinicians usually tailor the interval to the person’s circumstances. Someone whose exposure is continuing needs testing that continues too.

The second is a recent, specific exposure such as a needle-stick, a shared syringe or a sexual encounter with a partner known to carry the virus. Here the person may be asked to wait, not because the concern is trivial but because of the window period described earlier. An antibody test taken a fortnight after exposure will usually be negative even if infection has occurred. Clinicians often use an RNA test early, when the virus is already detectable, and repeat antibody testing later, typically at around 4–6 months according to CDC guidance for exposed health workers. Waiting, in this context, is a plan, not a dismissal.

Who is usually not tested routinely? Children and teenagers under 18 without a specific risk factor, since the universal recommendation begins at adulthood. Infants born to mothers with hepatitis C are a special case: antibodies cross the placenta, so a baby’s antibody test can be positive simply because the mother’s was. Pediatric guidance therefore favors RNA testing in infancy or antibody testing after 18 months of age, when maternal antibodies have faded. Someone who has already been treated and cleared the virus also does not need repeat antibody testing, because the antibody stays positive for life; if reinfection is a concern, RNA is the test that answers it.

Is hepatitis C tested for on an STD panel?

This is one of the most common questions people type into a search bar after a sexual health visit, and the honest answer is: often not. A standard sexually transmitted infection panel usually covers chlamydia, gonorrhea, syphilis and HIV. Hepatitis B and C are sometimes included and sometimes not, depending on the clinic’s protocol and on how the clinician assesses risk. If you want to know whether hepatitis C was included, the only reliable way is to ask or to read the results report line by line.

Why the omission? Hepatitis C is primarily a blood-borne virus. The CDC describes sexual transmission as possible but uncommon, and most likely in the presence of HIV, rough or bleeding contact, or multiple partners. In the everyday sense, hepatitis C is not classified with the infections that spread mainly through sex, which is why it drifts off standard panels.

That said, sexual health clinics see many people who fall into hepatitis C screening categories, and guidelines encourage them to offer the test alongside HIV. Men who have sex with men living with HIV are a group the CDC specifically identifies for hepatitis C screening, because of documented sexual transmission in that setting.

The practical takeaway is straightforward. A clean STI panel does not mean a negative hepatitis C test unless hepatitis C was on it. If you have never had the test as an adult, or you have had a specific exposure, request it by name. The blood is already being drawn; adding one more tube is rarely a problem, and the antibody test can be run from the same sample in most laboratories.

Hepatitis C antibody test versus hepatitis C RNA test: reading the results

Two tests, four possible combinations, and a fair amount of confusion. The hepatitis C antibody test tells you about history; the hepatitis C RNA test tells you about the present. Reading them together is what gives a result meaning. The table below reflects the interpretation framework used by the CDC and described for patients by MedlinePlus.

Antibody result	RNA result	What it usually means	Usual next step
Negative	Not tested	No evidence of past or current infection, provided exposure was not recent	No further testing unless ongoing risk or exposure within the window period
Positive	Detected	Current infection	Referral for liver assessment and treatment discussion
Positive	Not detected	Past infection that cleared, either on its own or after treatment; occasionally a false-positive antibody	No treatment needed; repeat RNA if recent exposure is possible
Negative	Detected	Very early infection before antibodies formed, or a weakened immune system that does not make antibodies well	Repeat testing and specialist review

A few words about the numbers on an RNA report. Laboratories often give a ‘viral load’, the quantity of virus per milliliter of blood. People understandably read a high number as a sicker liver, but hepatitis C does not work that way. Viral load does not correlate with the degree of liver damage and is used mainly to confirm that infection is present and, later, that treatment has removed it. Liver damage is assessed by other means, covered further on.

The fourth row is rare but real. People with advanced HIV, those on strong immune-suppressing medicines and some people on dialysis may not produce detectable antibodies. In these groups, clinicians sometimes go straight to RNA testing. If your immune system is compromised and your antibody test was negative, it is worth asking whether that applies to you.

Can a positive hep C antibody test be wrong?

A positive hep C antibody test with no virus detectable on RNA testing happens more often than people expect, and it is not usually a laboratory error. The most common explanation is that the person was infected at some point, their immune system cleared the virus, and the antibody remained as a permanent record. The World Health Organization estimates that about 30% of people, with a range of roughly 15–45%, clear a new hepatitis C infection spontaneously within six months without any treatment. Their antibody test will stay positive for the rest of their lives.

The second explanation is a true false positive. Antibody tests can react to proteins that resemble the viral target, and this is more likely in people with autoimmune conditions, during pregnancy, or in populations where the actual infection is rare. Because the test is designed to miss as few infections as possible, it accepts a certain number of false alarms in exchange. That is a reasonable trade for a screening test, but it means the antibody result alone should never be treated as a diagnosis.

The third explanation is the one that matters most: a positive antibody with negative RNA in someone whose exposure was recent. If the exposure happened within the last few months, a single negative RNA may not be the final word, and a repeat is sensible.

What a positive antibody with negative RNA does not mean is that you are contagious, that you need treatment, or that you have liver disease from hepatitis C. It also does not protect you. Antibodies to hepatitis C do not prevent reinfection the way antibodies to some other viruses do, which is why anyone who cleared the virus and still has exposure risk remains a candidate for periodic RNA testing.

What happens when the result is positive: the first conversation

The phone call or portal message usually says something like ‘your hepatitis C test is positive; please book an appointment’. It rarely says whether that means antibody alone or confirmed RNA, so the first job is to establish which result you actually have. If only the antibody was tested, the appointment may simply be to draw blood for RNA. If RNA has already been detected, the conversation is about a confirmed current infection.

What that first appointment covers, in most services, is a mix of information and history. Expect to be asked about possible exposures, not to assign blame but to identify household members or partners who may also benefit from testing. Expect questions about alcohol, because alcohol and hepatitis C damage the liver by overlapping routes and the combination is worse than either alone. Expect questions about other medicines and supplements, since some interact with antiviral treatment and some are hard on the liver in their own right.

Expect, too, to be told that chronic hepatitis C is a treatable infection. The World Health Organization reports that current antiviral treatment clears the virus in more than 95% of people treated. That is a guideline-level statement about populations, not a promise about any individual, and your own team will explain how it applies to you. But it changes the emotional weather of the appointment, and it is fair to hear it early.

Something else worth knowing: a diagnosis made now, at a routine screen, is a diagnosis made at the most favorable point. Many people learn they have hepatitis C only when the liver is already scarred. Learning about it while feeling well is, medically speaking, the good version of this news, even though it will not feel that way in the waiting room.

Which further tests usually follow a confirmed infection

Confirming the virus is step one. The next round of tests answers two questions: how much has the liver been affected, and is there anything else going on that changes the plan?

The liver question is answered in layers. Blood tests measure liver enzymes, proteins and clotting function; the CDC notes that some people with chronic infection have normal enzyme levels, so a normal panel does not rule out damage. Beyond blood, clinicians estimate fibrosis, which is scar tissue in the liver, using non-invasive methods. These include calculated scores built from routine blood results and an ultrasound-based scan that measures liver stiffness (stiffer tissue means more scarring). A liver biopsy, in which a small sample of tissue is removed with a needle, is now needed only occasionally. Whether fibrosis has progressed to cirrhosis, the stage at which scarring is extensive and the liver’s structure is distorted, is the single most important thing to establish, because it shapes treatment choice, monitoring and follow-up after treatment.

The ‘anything else’ question is answered by co-infection screening. The CDC recommends that everyone diagnosed with hepatitis C be tested for hepatitis B and HIV, since these viruses share transmission routes and interact with hepatitis C and its treatment. Hepatitis B in particular can reactivate during hepatitis C treatment in someone who did not know they carried it, so this is not a box-ticking exercise.

A genotype test may or may not be ordered. Genotype refers to which of the six main strains of the virus a person carries. It once determined which treatment was used and for how long. Newer regimens work across genotypes, so many services no longer test it routinely, though some still do, especially where cirrhosis is present or a previous treatment has failed.

How hepatitis C treatment works, in plain language

The medicines used for hepatitis C belong to a class called direct-acting antivirals, and the name describes the mechanism. Rather than boosting the immune system, as older treatments did, they act on the virus itself. Hepatitis C copies itself using a small set of viral proteins: an enzyme that cuts newly made viral protein into working pieces, a protein that organizes the copying machinery inside liver cells, and a polymerase that builds new strands of viral RNA. Direct-acting antivirals block one or more of these steps. A virus that cannot cut, organize or copy cannot sustain itself, and the infected cells are gradually cleared as no new virus replaces the old.

These medicines are taken by mouth, usually as a combination that targets more than one viral protein at once, which makes it much harder for the virus to develop resistance. The CDC describes typical treatment courses of 8–12 weeks. The exact regimen and length depend on whether cirrhosis is present, whether the person has been treated before, kidney function, other medicines and, in some cases, genotype. All of those decisions belong to the prescribing clinician, and this article deliberately gives no detail about specific regimens.

Side effects are generally described in guidance from the NHS and Mayo Clinic as mild for most people, with tiredness, headache and nausea the most frequently reported. This is a marked change from older interferon-based treatment, which lasted much longer and was often hard to tolerate.

What treatment does not do is repair the liver overnight. It removes the driver of ongoing damage. Whether and how far scarring improves afterward varies with how advanced it was, which is one more reason the fibrosis assessment before treatment matters so much.

What the following weeks and months usually look like

For most people, the stretch from diagnosis to treatment is measured in weeks rather than days, and it is filled with appointments more than symptoms. There is usually a visit to review the confirmatory RNA result and take a history, then blood tests and a fibrosis assessment, then a visit to discuss the treatment plan. Some services combine these steps; others space them out. Pharmacists often join the conversation to check for interactions with other medicines and supplements.

Once treatment starts, the routine is deliberately simple: take the medicine as prescribed, keep appointments, and report anything new. Blood tests during treatment are not always required, and when they are, they are usually few. Many people notice nothing at all beyond the act of remembering the medicine. Missed doses are the main thing that undermines treatment, so it helps to have a plan for travel, shift work or any period when routines wobble. Your team can suggest strategies; they have heard every variation.

The moment that matters most comes after the course ends. Guidelines define the treatment goal as a sustained virologic response, usually shortened to SVR12: no detectable hepatitis C RNA in the blood 12 weeks after the last dose. That blood test is the finish line. Skipping it is surprisingly common, because people feel well and the medicine is finished, but without it there is no confirmation that the virus has gone.

After a documented SVR12, most people without cirrhosis need no further hepatitis C follow-up unless they have new exposure. People with cirrhosis are a different story. Even after the virus is gone, scarred liver tissue carries a residual risk of liver cancer, and guidance from the CDC and WHO calls for ongoing surveillance, typically with periodic ultrasound. That is not a sign the treatment failed. It is the liver’s history being respected.

Living with the diagnosis while you wait: protecting your liver and the people around you

Between the positive result and the finish line there is ordinary life to live, and two practical concerns tend to dominate it.

The first is the liver itself. Alcohol is the clearest lever. Guidance from the NHS and Mayo Clinic advises people with hepatitis C to avoid or strictly limit alcohol, because the combination accelerates scarring. Weight, blood sugar and fat in the liver also matter, since metabolic liver disease and viral hepatitis reinforce each other. Vaccination against hepatitis A and hepatitis B is recommended by the CDC for people with chronic hepatitis C who are not already immune; a second liver infection on top of the first is worth preventing. Over-the-counter painkillers and herbal supplements deserve a conversation rather than a guess, because several are processed by the liver.

The second concern is other people. Hepatitis C travels in blood. The CDC is explicit that it is not spread by hugging, kissing, sharing food or utensils, coughing, sneezing or breastfeeding, unless nipples are cracked and bleeding. What does carry risk is anything that could move blood from one person to another: sharing razors, toothbrushes or nail clippers; sharing needles or any injecting or snorting equipment; unsterile tattooing or piercing. Sexual transmission is uncommon in long-term monogamous couples, and guidelines do not require condoms in that setting, though many couples choose them; risk is higher with HIV, multiple partners or contact involving blood.

Household members and sexual partners should be offered testing, not because transmission is likely but because it is easy to rule out. Children born to a mother with hepatitis C should be tested; the CDC estimates that about 6 in 100 infants born to infected mothers acquire the virus. Finding it early lets pediatric teams plan.

What people often get wrong about hepatitis C testing and results

Hepatitis C attracts more misunderstanding than most infections, partly because its story changed so fast. Here are the errors clinicians hear most, and what the evidence actually says.

‘I would know if I had it.’ Usually not. The WHO and CDC both note that most newly infected people have no symptoms, and chronic infection can stay silent for decades. Feeling well is not a test result.

‘My liver tests were normal, so I don’t have it.’ Liver enzymes fluctuate and can be normal in chronic infection. Only the antibody and RNA tests answer the question.

‘A positive antibody means I have hepatitis C.’ It means you were exposed. Roughly a third of infections clear on their own according to WHO estimates, and antibodies persist regardless. RNA is the deciding test.

‘I was tested years ago, so I’m covered.’ Only if nothing has happened since. A negative antibody test does not protect against future infection, and a past cleared infection does not prevent reinfection.

‘Treatment is long and miserable.’ That described interferon-based regimens. Current direct-acting antivirals are taken by mouth for typical courses of 8–12 weeks, per the CDC, and side effects are generally mild.

‘Hepatitis C is a sexually transmitted disease.’ It can be transmitted sexually, but the CDC classes this as uncommon. Blood-to-blood contact is the main route, which is also why it is often left off STI panels.

‘Once the virus is gone, the liver is fine.’ Clearing the virus stops further viral damage. Existing scarring may or may not regress, and cirrhosis, if present, still needs monitoring.

‘Only people who used drugs get it.’ Injection equipment is the most frequent route today, but transfusions before blood screening, medical procedures with unsterile equipment, dialysis, needle-sticks and birth all account for infections. The universal screening recommendation exists precisely because risk-based lists missed so many people.

Questions to ask your care team

A short list, carried into the appointment, does more for understanding than an hour of searching afterward. These are the questions that tend to unlock the most useful answers.

• Was my result antibody only, or was RNA also tested? If not, when will RNA be done?
• What do my liver blood tests show, and do I need a fibrosis scan or score before we plan treatment?
• Do I have any signs of cirrhosis, and how does that change my treatment and follow-up?
• Have I been tested for hepatitis B and HIV, and do I need hepatitis A or B vaccination?
• Which of my current medicines, supplements or herbal products could interact with treatment or affect my liver?
• How long would my course of treatment be expected to last, and how many visits or blood tests will it involve?
• What side effects should I watch for, and which ones should prompt a call?
• When will the post-treatment RNA test be, and how will I receive the result?
• Who in my household or among my partners should be offered testing, and can you help arrange it?
• If I have cirrhosis, what surveillance will I need after treatment and for how long?
• Is there anything about pregnancy, breastfeeding or planning a family that we should discuss now?
• Who do I contact between appointments if something changes?

Two of these deserve emphasis. The first question, about RNA, prevents the most common failure in the whole pathway: an antibody result that never gets confirmed. The question about the post-treatment RNA test prevents the second most common failure: a course completed but never verified. Everything in between is important, but those two bookends decide whether the process reaches an actual conclusion.

Bring a pen, or ask whether the visit summary will be sent to your patient portal. Diagnoses that arrive unexpectedly are hard to absorb in real time, and there is no shame in asking for the same explanation twice.

When to call your doctor

Most of the hepatitis C pathway is unhurried, but there are signs that call for prompt medical attention, whether you are waiting for confirmation, undergoing treatment or being followed after cirrhosis was found.

Contact your care team the same day, or use urgent care services, if you notice:

• yellowing of the skin or the whites of the eyes (jaundice), or urine that has turned dark brown;
• swelling of the abdomen or legs that is new or increasing;
• confusion, unusual drowsiness or difficulty concentrating, which in someone with liver disease can signal a build-up of toxins the liver is no longer clearing;
• vomiting blood, passing black or tarry stools, or bleeding that will not stop;
• severe pain in the upper right abdomen, or a high fever;
• a rash, facial swelling or breathing difficulty after starting a new medicine.

Call within a day or two, rather than waiting for the next scheduled visit, if you have persistent nausea and cannot keep medicines down, if you have missed several doses of antiviral treatment, if you start a new prescription, over-the-counter product or supplement during treatment, or if you learn that a household member or partner has tested positive.

If you are pregnant or become pregnant during the process, tell the team promptly; timing of treatment around pregnancy and breastfeeding is a decision made jointly with obstetric and liver specialists, and CDC guidance supports screening in every pregnancy precisely so that planning can begin early.

Finally, call if the system has gone quiet. If weeks have passed since a positive antibody result and nobody has arranged RNA testing, or if your post-treatment test has not been scheduled, chase it. The pathway works when it is completed, and the person best placed to notice a gap is often the one living it.

Frequently asked questions

Is hep C on an STD panel?

Often not. Standard STI panels usually test for chlamydia, gonorrhea, syphilis and HIV; hepatitis C is added only when the clinic’s protocol or your risk assessment calls for it. Because hepatitis C spreads mainly through blood rather than sex, it is not classed with the core sexually transmitted infections. If you want it checked, ask for the hepatitis C antibody test by name and confirm it appears on the results report.

What if I test positive for hep C?

First, find out whether the positive result is antibody only or confirmed by an RNA test. Antibody alone means past exposure; RNA detected means current infection. With current infection, your clinician will check liver blood tests, estimate scarring, screen for hepatitis B and HIV, and discuss direct-acting antiviral treatment, which the CDC describes as typically lasting 8–12 weeks. You are not contagious through everyday contact, and the infection is treatable.

How do you test for a virus like hepatitis C?

Laboratories look for two footprints. An antibody test detects the immune proteins your body makes after meeting the virus; a positive result shows exposure at some point. An RNA test, done by PCR, detects the virus’s own genetic material and shows whether it is present now. Screening starts with the antibody test and confirms with RNA, often automatically from the same blood sample.

How soon after exposure does a hepatitis C antibody test turn positive?

According to the CDC, antibodies are usually detectable 8–11 weeks after exposure, though in some people it takes longer, so a negative antibody result within the first months after a needle-stick or shared syringe is not conclusive. Viral RNA can typically be detected within 1–2 weeks, which is why clinicians often use an RNA test early and repeat antibody testing at around 4–6 months.

What does a positive hep C antibody test with negative RNA mean?

It usually means you were infected at some point and your immune system cleared the virus; the WHO estimates this happens in about 30% of new infections. Occasionally the antibody is a false positive. Either way, you do not have current infection, you do not need treatment, and you cannot pass the virus on. The antibody stays positive for life and does not protect against reinfection.

Do I need a hepatitis C RNA test if my antibody test was negative?

Usually not. A negative antibody test, taken well after any possible exposure, is considered sufficient to rule out infection. Two exceptions exist: a very recent exposure, when antibodies may not have formed yet, and a weakened immune system, such as advanced HIV or dialysis, when antibodies may never appear. In those situations, clinicians may order RNA testing directly.

Can I have hepatitis C with normal liver blood tests?

Yes. Liver enzymes fluctuate in chronic hepatitis C and can be normal for long periods even while scarring progresses. The CDC notes that normal enzyme levels do not exclude infection or liver damage. Only the antibody and RNA tests diagnose hepatitis C, and the degree of fibrosis is assessed separately with blood-based scores or a liver stiffness scan.

Should I be tested for hepatitis C during pregnancy?

Yes. The CDC recommends hepatitis C testing during every pregnancy, regardless of previous results. Identifying infection allows the obstetric team to plan delivery care, arrange testing for the baby, and discuss the timing of antiviral treatment, which is usually planned around pregnancy and breastfeeding by the treating team. Breastfeeding is not considered a transmission risk unless nipples are cracked and bleeding.

Can hepatitis C come back after treatment?

Once a sustained virologic response is confirmed, meaning no RNA detected 12 weeks after treatment ends, relapse of the original infection is uncommon. Reinfection through new blood exposure is possible, because antibodies do not provide immunity. Anyone with ongoing risk is advised to have periodic RNA testing, and people with cirrhosis need continued liver surveillance regardless of viral status.

Do I need a hepatitis C test if I have no symptoms and no risk factors?

Yes, once. The CDC recommends that every adult aged 18 or older be tested at least once, because most people with chronic infection feel well and many cannot identify how they were exposed. The universal recommendation exists precisely because risk-based screening missed a large share of infections. Ask for the test at your next routine blood draw.

References

• CDC: Testing for Hepatitis C
• CDC MMWR: Recommendations for Hepatitis C Screening Among Adults
• WHO: Hepatitis C fact sheet
• NHS: Hepatitis C

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.